SCHEMBL7189548

SCHEMBL7189548

COc1c(Cl)ccc(Cl)c1C(=O)P(=O)(C(=O)c1c(C)cc(C)cc1C)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 9/20 0.50
TAS1R1 Q7RTX1 9/20 0.50
TAS1R2 Q8TE23 7/20 0.50
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.36
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
HTT P42858 2/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
NPC1 O15118 1/20 0.34
GRM4 Q14833 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182506 0.92 TAS1R3 (0.45) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7189211 0.91 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7183280 0.90 ALDH1A1 (0.50) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7178030 0.90 ALDH1A1 (0.45) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7189319 0.88 ALDH1A1 (0.46) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7186760 0.86 ALDH1A1 (0.49) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7175785 0.86 POLB (0.42) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7187679 0.86 ALDH1A1 (0.54) TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E
SCHEMBL7184527 0.85 MEN1 (0.38) TAS1R3TAS1R1TAS1R2ALDH1A1KMT2A
SCHEMBL7182197 0.85 MEN1 (0.35) TAS1R3TAS1R1TAS1R2KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TAS1R3 2990/4885TAS1R1 3374/4885TAS1R2 3865/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TAS1R3 3176/4885TAS1R1 3927/4885TAS1R2 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.